

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

INCARA PHARMACEUTICALS CORP
Form SC 13G/A
February 01, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Incara Pharmaceuticals Corporation

(Name of Issuer)

Common Stock

(Title of Class of Securities)

45324E103

(CUSIP Numbers)

December 31, 2001

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

NAME OF REPORTING PERSON

1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

Clayton I. Duncan

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

2 Not Applicable (a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

		SOLE VOTING POWER
NUMBER OF SHARES	5	809,572

		SHARED VOTING POWER
BENEFICIALLY OWNED BY	6	0

		SOLE DISPOSITIVE POWER
EACH REPORTING PERSON	7	809,572

		SHARED DISPOSITIVE POWER
WITH	8	0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

809,572

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

Not Applicable

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.3%

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

IN

Item 1(a) Name of Issuer

Incara Pharmaceuticals Corporation

Item 1(b) Address of Issuer's Principal Executive Offices

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box
14287, Research Triangle Park, NC 27709-4287

Item 2(a) Name of Person Filing

Clayton I. Duncan

Item 2(b) Address of Principal Business Office, or, if None, Residence

79 T.W. Alexander Dr., 4401 Research Commons, Suite 200, P.O. Box

Edgar Filing: INCARA PHARMACEUTICALS CORP - Form SC 13G/A

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

Not Applicable

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 1, 2002

Date

/s/ Clayton I. Duncan

Clayton I. Duncan